Gum disease vaccine developer Denteric has spun out of Melbourne with series A capital from the institution, the Biomedical Translation Fund and CSL.
Denteric, a UK-based periodontal gum disease vaccine developer spun out of University of Melbourne, attracted $14m in series A funding today from investors including the university and the Australian government-backed Biomedical Translation Fund.
Biotechnology firm CSL also contributed to the round. The Biomedical Translation Fund is managed by Brandon Capital.
Denteric is developing a vaccine treatment for periodontal gum disease. Also known as periodontitis, the disease occurs when plaque from teeth becomes lodged beneath the gum line and…
